232 results on '"Cohen, Stanley"'
Search Results
2. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
- Author
-
Menter, Alan, Cohen, Stanley, Kay, Jonathan, Strand, Vibeke, Gottlieb, Alice, Hanauer, Stephen, Eduru, Sravan Kumar, Buschke, Susanne, Lang, Benjamin, Liesenfeld, Karl-Heinz, Schaible, Jennifer, and McCabe, Dorothy
- Subjects
- *
PSORIASIS , *DRUG efficacy , *CONFIDENCE intervals , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *BLIND experiment , *DESCRIPTIVE statistics , *ANALYSIS of covariance , *RESEARCH funding , *ADALIMUMAB , *STATISTICAL sampling , *DATA analysis software , *PATIENT safety , *EVALUATION - Abstract
Background: BI 695501 is an FDA-approved biosimilar to adalimumab reference product (RP). VOLTAIRE-X was a randomized clinical trial to assess outcomes with a biosimilar monoclonal antibody in line with the FDA requirements for designation as an 'interchangeable' biosimilar. Objective: The aim of this study was to assess whether multiple switches between adalimumab RP and BI 695501 lead to equivalent pharmacokinetics and a similar safety and immunogenicity profile compared with continuous adalimumab RP. Methods: We conducted a phase III, double-blind, randomized controlled trial between July 19, 2017, and April 16, 2019. There were 49 investigational sites across Europe and North America. Of 323 screened patients with moderate-to-severe chronic plaque psoriasis, 259 were treated with adalimumab RP during the run-in period. Of these, 118 and 120 were randomized to the continuous or switching arms, respectively. Interventions consisted of a run-in period with adalimumab RP 80 mg subcutaneously (SC) on Day 1, then 40 mg SC every other week (EOW) Weeks 2–12. Patients were then randomized to receive adalimumab RP 40 mg EOW Weeks 14–48 (continuous arm) or BI 695501 40 mg Weeks 14 and 16, adalimumab RP 40 mg Weeks 18 and 20, and BI 695501 40 mg EOW Weeks 22 to 48 (switching arm); all interventions were given SC. Primary endpoints were pharmacokinetics parameters, area under the plasma concentration–time curve (AUCτ,30–32) and maximum observed drug plasma concentration (Cmax,30–32), measured after the third switch during the Week 30–32 dosing interval. Results: 238 patients (mean [standard deviation] age 44.9 [13.8]; 66.0% male) were treated in the switching (n = 118) or continuous arms (n = 120). Adjusted mean Cmax,30–32 was 7.08 and 7.00 μg/mL in the switching and continuous treatment arms, respectively; adjusted mean AUCτ,30–32 was 2025.8 and 1925.9 μg h/mL. Point estimate for mean ratio for AUCτ,30–32 was 105.2% (90.2% confidence interval [CI] 96.6–114.6), and 101.1% (90.2% CI 93.3–109.7) for Cmax,30–32. Both CIs were within a predefined bioequivalence range of 80.0–125.0%. Treatment-emergent adverse events led to discontinuation in 0.8% and 1.7% of patients in the switching and continuous treatment arms, and Psoriasis Area and Severity Index (PASI) scores were highly similar in the two arms across the entire trial period. Conclusions: Pharmacokinetic equivalence was demonstrated, with highly similar efficacy and immunogenicity, and comparable safety observed in patients with chronic plaque psoriasis who received either adalimumab RP continuously or who switched between adalimumab RP and BI 695501. Trial Registration: ClinicalTrials.gov: NCT03210259 (registered July 2017); Eudract.ema.europa.eu: 2016-002254-20. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Oral surveillance and JAK inhibitor safety: the theory of relativity.
- Author
-
Winthrop, Kevin L. and Cohen, Stanley B.
- Abstract
The published results of the post-marketing ORAL Surveillance study, which compared the Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with rheumatoid arthritis who have cardiovascular risk factors, have led to changes in the recommendations for the use of JAK inhibitors. Although new safety signals have emerged for tofacitinib, namely malignancy and cardiovascular disease, it should be noted that these signals are relative to those seen with TNF blockers. The new data further raise our intrigue that venous thromboembolism might be a true risk related to JAK inhibition. Reassuringly, the totality of the findings from this newly published study and the other data collected to date suggest that JAK inhibitors can be used safely at approved doses by many patients with rheumatoid arthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
- Author
-
Conaghan, Philip, Cohen, Stanley, Burmester, Gerd, Mysler, Eduardo, Nash, Peter, Tanaka, Yoshiya, Rigby, William, Patel, Jayeshkumar, Shaw, Tim, Betts, Keith A., Patel, Pankaj, Liu, Jianzhong, Sun, Rochelle, and Fleischmann, Roy
- Subjects
- *
RHEUMATOID arthritis , *HERPES zoster , *ADALIMUMAB , *C-reactive protein , *AUTOIMMUNE diseases - Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring long-term treatment. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, is a new treatment for RA. The benefit–risk profile of a medication is best understood by evaluating the number needed to treat (NNT) and the number needed to harm (NNH). This analysis evaluated the comparative risk–benefit of UPA versus adalimumab (ADA). Methods: Post-hoc analyses were performed using data from the SELECT-COMPARE trial of UPA versus placebo (PBO) and UPA versus ADA among patients with active RA who remained on stable methotrexate (MTX) treatment and had an inadequate response; patients who failed to achieve response were rescued by predefined criteria—PBO or ADA switch to UPA, and UPA switch to ADA (all patients on PBO were switched to UPA at week 26). This analysis assessed efficacy and adverse events of special interest (AESIs) at week 26, 48, and 156 (3 years). NNT and NNH (95% confidence intervals) values were calculated between UPA versus ADA for all time points, and between UPA versus PBO for week 26. NNT and NNH values were applied to a hypothetical cohort of 100 patients to estimate the comparative efficacy and safety profiles. Results: UPA consistently showed greater efficacy than ADA, as evidenced by NNT values < 10 for achievement of Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP) of < 2.6 and ≤ 3.2, respectively, and functional improvement. Based on indices for disease assessment other than the DAS28-CRP, remission outcomes were higher with UPA versus ADA over 26 weeks (NNTs: 7–12), 48 weeks (NNTs: 9–16), and 156 weeks (NNTs: 9–15). With the exception of herpes zoster, other AESIs demonstrated a similar risk with UPA versus ADA. Conclusion: In patients with active RA despite MTX use, UPA demonstrated an incremental achievement of clinical outcomes compared to ADA together with a similar profile of AESIs with ADA (with the exception of herpes zoster). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.
- Author
-
Cohen, Stanley, Wells, Alvin F., Curtis, Jeffrey R., Dhar, Rajat, Mellors, Theodore, Zhang, Lixia, Withers, Johanna B., Jones, Alex, Ghiassian, Susan D., Wang, Mengran, Connolly-Strong, Erin, Rapisardo, Sarah, Gatalica, Zoran, Pappas, Dimitrios A., Kremer, Joel M., Saleh, Alif, and Akmaev, Viatcheslav R.
- Subjects
- *
LONGITUDINAL method , *DISEASE progression , *SCIENTIFIC observation , *RHEUMATOID arthritis , *RNA sequencing , *ABATACEPT - Abstract
Introduction: Timely matching of patients to beneficial targeted therapy is an unmet need in rheumatoid arthritis (RA). A molecular signature response classifier (MSRC) that predicts which patients with RA are unlikely to respond to tumor necrosis factor-α inhibitor (TNFi) therapy would have wide clinical utility. Methods: The protein–protein interaction map specific to the rheumatoid arthritis pathophysiology and gene expression data in blood patient samples was used to discover a molecular signature of non-response to TNFi therapy. Inadequate response predictions were validated in blood samples from the CERTAIN cohort and a multicenter blinded prospective observational clinical study (NETWORK-004) among 391 targeted therapy-naïve and 113 TNFi-exposed patient samples. The primary endpoint evaluated the ability of the MSRC to identify patients who inadequately responded to TNFi therapy at 6 months according to ACR50. Additional endpoints evaluated the prediction of inadequate response at 3 and 6 months by ACR70, DAS28-CRP, and CDAI. Results: The 23-feature molecular signature considers pathways upstream and downstream of TNFα involvement in RA pathophysiology. Predictive performance was consistent between the CERTAIN cohort and NETWORK-004 study. The NETWORK-004 study met primary and secondary endpoints. A molecular signature of non-response was detected in 45% of targeted therapy-naïve patients. The MSRC had an area under the curve (AUC) of 0.64 and patients were unlikely to adequately respond to TNFi therapy according to ACR50 at 6 months with an odds ratio of 4.1 (95% confidence interval 2.0–8.3, p value 0.0001). Odds ratios (3.4–8.8) were significant (p value < 0.01) for additional endpoints at 3 and 6 months, with AUC values up to 0.74. Among TNFi-exposed patients, the MSRC had an AUC of up to 0.83 and was associated with significant odds ratios of 3.3–26.6 by ACR, DAS28-CRP, and CDAI metrics. Conclusion: The MSRC stratifies patients according to likelihood of inadequate response to TNFi therapy and provides patient-specific data to guide therapy choice in RA for targeted therapy-naïve and TNFi-exposed patients. Plain Language Summary: A blood-based molecular signature response classifier (MSRC) integrating next-generation RNA sequencing data with clinical features predicts the likelihood that a patient with rheumatoid arthritis will have an inadequate response to TNFi therapy. Treatment selection guided by test results, with likely inadequate responders appropriately redirected to a different therapy, could improve response rates to TNFi therapies, generate healthcare cost savings, and increase rheumatologists' confidence in prescribing decisions and altered treatment choices. The MSRC described in this study predicts the likelihood of inadequate response to TNFi therapies among targeted therapy-naïve and TNFi-exposed patients in a multicenter, 24-week blinded prospective clinical study: NETWORK-004. Patients with a molecular signature of non-response are less likely to have an adequate response to TNFi therapies than those patients lacking the signature according to ACR50, ACR70, CDAI, and DAS28-CRP with significant odds ratios of 3.4–8.8 for targeted therapy-naïve patients and 3.3–26.6 for TNFi-exposed patients. This MSRC provides a solution to the long-standing need for precision medicine tools to predict drug response in rheumatoid arthritis—a heterogeneous and progressive disease with an abundance of therapeutic options. These data validate the performance of the MSRC in a blinded prospective clinical study of targeted therapy-naïve and TNFi therapy-exposed patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
- Author
-
Smolen, Josef S, Cohen, Stanley B, Tony, Hans-Peter, Scheinberg, Morton, Kivitz, Alan, Balanescu, Andra, Gomez-Reino, Juan, Cen, Liyi, Poetzl, Johann, Shisha, Tamas, and Kollins, Dmitrij
- Subjects
- *
B cells , *PATIENT safety , *RHEUMATOID arthritis , *RITUXIMAB , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *DESCRIPTIVE statistics , *BIOSIMILARS , *PHARMACODYNAMICS - Abstract
Objectives This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference rituximab (Ref-RTX) up to week 52 of the ASSIST-RA study. Methods Patients were randomized to SDZ-RTX or Ref-RTX in combination with methotrexate according to the RTX label. The primary endpoint was analysed at week 24. Responders (28-joint DAS [DAS28] decrease from baseline >1.2) at week 24 with residual disease activity (DAS28 ≥2.6) were eligible for a second treatment course between week 24 and 52. Endpoints after week 24 included change from baseline in peripheral B cells, DAS28, ACR 20% response rate (ACR20), Clinical and Simplified Disease Activity Indexes (CDAI, SDAI) and HAQ disability index (HAQ-DI). Safety and immunogenicity were assessed by the incidence of adverse events and antidrug antibodies. Results Primary and secondary endpoints up to week 24 were met. Overall, 260/312 randomized patients completed treatment up to week 52. SDZ-RTX resulted in B cell concentrations over time similar to Ref-RTX. The efficacy of SDZ-RTX was similar to Ref-RTX up to week 52, as measured by DAS28, ACR20/50/70, CDAI, SDAI and HAQ-DI. Safety of SDZ-RTX was similar to Ref-RTX regarding frequency, type and severity of adverse events, which were consistent with the known Ref-RTX safety profile. The incidence of antidrug antibodies was low and transient similarly across treatment groups. Conclusion SDZ-RTX demonstrated similar B cell concentrations over time, efficacy, safety and immunogenicity to Ref-RTX over 52 weeks of the ASSIST-RA study. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.
- Author
-
Cohen, Stanley, Akmaev, Viatcheslav R., Withers, Johanna B., and Connolly-Strong, Erin
- Subjects
- *
LONGITUDINAL method , *EMPLOYEE ownership , *SCIENTIFIC observation , *VAGUS nerve stimulation , *TUMOR necrosis factors - Abstract
A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- Inhibitors: The NETWORK-004 Prospective Observational Study Our study combined machine learning and network biology to further refine our molecular signature response classifier (MSRC) test, which predicts non-response to tumor necrosis factor-alpha inhibitors (TNFi) in rheumatoid arthritis (RA). Keywords: Rheumatoid arthritis; Precision medicine; Molecular signature response classifier EN Rheumatoid arthritis Precision medicine Molecular signature response classifier 309 311 3 02/06/22 20220201 NES 220201 This reply refers to the comment available online at https://doi.org/10.1007/s40744-021-00330-y, https://doi.org/10.1007/s40744-021-00386-w. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
8. Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial.
- Author
-
Cohen, Stanley, Tuckwell, Katie, Katsumoto, Tamiko R., Zhao, Rui, Galanter, Joshua, Lee, Chin, Rae, Julie, Toth, Balazs, Ramamoorthi, Nandhini, Hackney, Jason A., Berman, Alberto, Damjanov, Nemanja, Fedkov, Dmytro, Jeka, Slawomir, Chinn, Leslie W., Townsend, Michael J., Morimoto, Alyssa M., Genovese, Mark C., Porto, Alejandro, and Granel, Amelia
- Subjects
- *
ANTI-inflammatory agents , *AUTOANTIBODIES , *B cells , *BIOMARKERS , *COMPARATIVE studies , *CYTOKINES , *LONGITUDINAL method , *METHOTREXATE , *PLACEBOS , *RHEUMATOID arthritis , *STATISTICAL sampling , *PROTEIN-tyrosine kinase inhibitors , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *ADALIMUMAB , *PHARMACODYNAMICS , *EVALUATION - Abstract
Objective: To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA). Methods: Patients with RA and an inadequate response to methotrexate (MTX) (cohort 1; n = 480) were randomized to receive fenebrutinib (50 mg once daily, 150 mg once daily, or 200 mg twice daily), adalimumab (40 mg every other week), or placebo. Patients with RA and an inadequate response to tumor necrosis factor inhibitors (cohort 2; n = 98) received fenebrutinib (200 mg twice daily) or placebo. Both cohorts continued MTX therapy. Results: In cohort 1, the percentages of patients in whom American College of Rheumatology 50% improvement criteria (ACR50) was achieved at week 12 were similar in the fenebrutinib 50 mg once daily and placebo groups, and were higher in the fenebrutinib 150 mg once daily group (28%) and 200 mg twice daily group (35%) than in the placebo group (15%) (P = 0.016 and P = 0.0003, respectively). Fenebrutinib 200 mg twice daily and adalimumab (36%) were comparable (P = 0.81). In cohort 2, ACR50 was achieved in more patients receiving fenebrutinib 200 mg twice daily (25%) than placebo (12%) (P = 0.072). The most common adverse events in the fenebrutinib groups included nausea, headache, anemia, and upper respiratory tract infections. Fenebrutinib had significant effects on myeloid and B cell biomarkers (CCL4 and rheumatoid factor). Fenebrutinib and adalimumab caused overlapping as well as distinct changes in B cell and myeloid biomarkers. Conclusion: Fenebrutinib demonstrates efficacy comparable to adalimumab in patients with an inadequate response to MTX, and safety consistent with existing immunomodulatory therapies for RA. These data support targeting both B and myeloid cells via this novel mechanism for potential efficacy in the treatment of RA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al.
- Author
-
Cohen, Stanley B., Mellors, Theodore, and Bergman, Martin J.
- Subjects
- *
BIOMARKERS , *ANTI-inflammatory agents , *INDIVIDUALIZED medicine , *MACHINE learning , *TREATMENT effectiveness , *RHEUMATOID arthritis , *ADALIMUMAB , *ETANERCEPT - Published
- 2021
- Full Text
- View/download PDF
10. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
- Author
-
Cohen, Stanley B., Radominski, Sebastiao C., Kameda, Hideto, Kivitz, Alan J., Tee, Michael, Cronenberger, Carol, Zhang, Min, Hackley, Sarah, Rehman, Muhammad I., von Richter, Oliver, and Alten, Rieke
- Subjects
- *
RHEUMATOID arthritis , *INFLIXIMAB , *ADVERSE health care events - Abstract
Objective: Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78 weeks or who switched from reference infliximab (Remicade®) sourced from the EU (IFX-EU) at week 30 or week 54 in the REFLECTIONS B537-02 study. Methods: In this phase III, double-blind, active-controlled study, patients with moderate-to-severe active RA were initially randomized to PF-SZ-IFX or IFX-EU, each with methotrexate (treatment period [TP] 1; N = 650). At week 30, patients receiving PF-SZ-IFX continued PF-SZ-IFX; patients receiving IFX-EU were re-randomized to continue IFX-EU or switch to PF-SZ-IFX (TP2; n = 566). From weeks 54 to 78, all patients received open-label treatment with PF-SZ-IFX (TP3; n = 505). Efficacy, safety, and immunogenicity data were analyzed during TP3. Results: Efficacy was sustained and comparable across groups at week 78, with American College of Rheumatology criteria for ≥ 20% clinical improvement response rates of 75.9% (biosimilar group), 77.8% (week 30 switch group), and 68.3% (week 54 switch group). The incidence of treatment-emergent adverse events was 28.9%, 29.4%, and 30.2%, respectively. The proportion of patients who were antidrug antibody (ADA) positive and neutralizing antibody positive (as a percentage of ADA-positive patients) was stable and comparable between groups. Conclusions: Results to week 78 continue to support the efficacy, safety, and immunogenicity of PF-SZ-IFX in patients with moderate-to-severe active RA. There were no clinically meaningful differences between groups, independent of a single treatment transition from IFX-EU to PF-SZ-IFX at week 30 or week 54. Trial Registration Number: NCT02222493. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.
- Author
-
Cohen, Stanley B., Kremer, Joel M., Dandreo, Kimberly J., Reed, George W., Magner, Robert, Shan, Ying, Kafka, Shelly, DeHoratius, Raphael J., Ellis, Lorie, and Parenti, Dennis
- Subjects
- *
RHEUMATOID arthritis , *DRUG prices , *DIRECT costing - Abstract
Introduction: Dose escalation of infliximab in both primary and secondary nonresponders is widely reported; however, the usefulness of dose escalation has been disputed. The objective of this analysis is to evaluate trends in clinical efficacy following multiple infliximab dose escalations in patients with rheumatoid arthritis (RA). Methods: Patients enrolled in a US RA registry were included if they initiated infliximab at 3 mg/kg every 8 weeks, received ≥ 1 infliximab dose escalation within 12 months of initiation, and had ≥ 1 visit following dose escalation. Trends in mean Clinical Disease Activity Index (CDAI) and Health Assessment Questionnaire (HAQ) scores from visits following dose escalations were evaluated. Results: In patients who received 2 or 3 dose escalations, the initial (1 or 2) dose escalations resulted in reduced mean CDAI scores, but subsequent escalations did not further reduce disease activity. In patients who received ≥ 4 dose escalations, mean CDAI scores did not further reduce disease activity over time. Mean HAQ scores were stable over time in patients who received 2 or 3 dose escalations. In patients who received ≥ 4 dose escalations, mean HAQ scores decreased following 1 dose escalation but progressively increased following subsequent dose escalations. Conclusion: Initial dose escalations (from 3 mg/kg to the equivalent of approximately 5 to 7 mg/kg) may be useful in controlling disease activity; however, there may be diminishing clinical benefit of further escalations, which can also increase the potential risk for infection and increase incremental drug costs. Key Points: • Initial infliximab dose escalations (1 to 2) may be useful in lowering disease activity in patients with rheumatoid arthritis. • There does not appear to be a clinical benefit in infliximab dose escalations above the equivalent of 5 to 7 mg/kg. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial.
- Author
-
Cohen, Stanley, Samad, Ahmed, Karis, Elaine, Stolshek, Bradley S., Trivedi, Mona, Zhang, Hao, Aras, Girish A., Kricorian, Greg, and Chung, James B.
- Subjects
- *
RHEUMATOID arthritis , *PSORIATIC arthritis , *RANDOMIZED controlled trials , *ETANERCEPT , *TUMOR necrosis factors , *THERAPEUTICS , *PAIN management - Abstract
Introduction: Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of prescribed medications. To improve the patient experience, a new phosphate-free formulation of etanercept was evaluated for reduced ISP associated with administration. Methods: This phase 3b, multicenter, randomized, double-blind, cross-over study compared the prior formulation of etanercept to a phosphate-free formulation. Etanercept-naïve adults with RA or PsA indicated for treatment with etanercept were eligible. Patients were randomized (1:1) to receive both etanercept formulations (50 mg) in one of two crossover sequences: prior formulation followed by phosphate-free formulation (sequence AB) or phosphate-free formulation followed by prior formulation (sequence BA) at visits 1 week apart. Patients self-reported ISP using a fit-for-purpose 100-mm visual analog scale within 30 s after injection. Safety outcomes included incidence of treatment-emergent adverse events. Mixed-effects analysis of variance model was used to assess ISP, with treatment, study period, sequence, and disease indication as fixed-effect covariates and patient-within-sequence as random effect. Results: A total of 111 patients enrolled (56 sequence AB; 55 sequence BA). Mean ISP score for prior formulation was 23.1 mm and for phosphate-free formulation was 19.1 mm (mean difference − 4 mm; 95% confidence interval: − 8.0, 0.0; P = 0.048). Patients with the highest ISP scores from the prior formulation (by quartile cut points) had the largest reduction in pain with phosphate-free formulation. Injection site reactions were few in number and similar between formulations; no new safety signals were observed. Conclusions: The new phosphate-free formulation of etanercept had statistically significantly lower mean pain scores than the prior formulation, with largest pain reductions observed among patients who reported highest pain with the prior formulation. Trial Registration: ClinicalTrials.gov: NCT02986139. Funding: Amgen Inc, Thousand Oaks, CA USA. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
- Author
-
Baker, Matthew C., Kavanagh, Sarah, Cohen, Stanley, Matsumoto, Alan K., Dikranian, Ara, Tesser, John, Kivitz, Alan, Alataris, Konstantinos, and Genovese, Mark C.
- Subjects
- *
RHEUMATOID arthritis treatment , *BIOTHERAPY , *RHEUMATOID arthritis diagnosis , *C-reactive protein , *VAGUS nerve , *ANTIRHEUMATIC agents , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *BLIND experiment , *QUESTIONNAIRES , *DESCRIPTIVE statistics , *STATISTICAL sampling , *DATA analysis software , *NEURAL stimulation , *TRANSCUTANEOUS electrical nerve stimulation - Abstract
Objective: Preliminary evidence suggests that vagus nerve stimulation (VNS) may have some benefit in patients with rheumatoid arthritis (RA); however, prior studies have been small and/or uncontrolled; this study aimed to address that gap. Methods: This randomized, double‐blind, sham‐controlled trial enrolled patients aged 18 to 75 years with active RA who had failed conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) and were naïve to biologic and/or targeted synthetic DMARDs. All patients received an auricular vagus nerve stimulator and were randomized 1:1 to active stimulation or sham. The primary endpoint was the proportion of patients achieving 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Secondary endpoints included mean changes in disease activity score of 28 joints with C‐reactive protein (DAS28‐CRP) and Health Assessment Questionnaire‐Disability Index (HAQ‐DI). Results: A total of 113 patients (mean age 54 years; 82% female) enrolled, and 101 patients (89.4%) completed week 12. ACR20 response at week 12 was 25.0% for active stimulation versus 26.9% for sham (difference vs. sham, −1.9; 95% CI, −18.8, 14.9, P = 0.823). The least square mean ± SE change in DAS28‐CRP was −0.95 ± 0.16 for active stimulation and −0.66 ± 0.16 for sham (P = 0.201); in HAQ‐DI it was −0.19 ± 0.06 for active stimulation and −0.02 ± 0.06 for sham (P = 0.044). Adverse events occurred in 17 patients (15%); all were mild or moderate. Conclusion: Auricular VNS did not meaningfully improve RA disease activity. If VNS with other modalities is pursued in the future for the treatment of RA, larger, controlled studies will be needed to understand its utility. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.
- Author
-
Burmester, Gerd R., Coates, Laura C., Cohen, Stanley B., Tanaka, Yoshiya, Vranic, Ivana, Nagy, Edward, Lazariciu, Irina, Chen, All-shine, Kwok, Kenneth, Fallon, Lara, and Kinch, Cassandra
- Subjects
- *
RHEUMATOID arthritis , *HERPES zoster , *THROMBOEMBOLISM , *OFF-label use (Drugs) , *PSORIATIC arthritis , *REGIONAL differences - Abstract
Introduction: The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spontaneous and voluntary adverse event (AE) reports have been published for RA, but not PsA. To inform the real-world safety profile of tofacitinib in PsA, we evaluated AE reports submitted to the Pfizer safety database (including RA data for context). Methods: Endpoints included AEs, serious AEs (SAEs), AEs of special interest (AESIs; serious infections, herpes zoster, cardiovascular events, malignancies, venous thromboembolism), and fatal cases. Exposure was estimated using IQVIA global commercial sales data. Number, frequency, and reporting rates (RRs; number of events/100 patient-years' [PY] exposure) were summarized by indication and formulation (immediate release [IR] 5 or 10 mg twice daily], modified release [MR] 11 mg once daily, or all tofacitinib). The data-collection period differed by indication (PsA: 14 December 2017 [US approval, IR/MR] to 6 November 2021; RA: 6 November 2012 [US approval, IR] to 6 November 2021; MR approval, 24 February 2016). Results: A total of 73,525 case reports were reviewed (PsA = 5394/RA = 68,131), with 20,706/439,370 PY (PsA/RA) of exposure. More AEs were reported for IR versus MR (IR/MR: PsA = 8349/7602; RA = 137,476/82,153). RRs for AEs (IR/MR: PsA = 59.6/113.4; RA = 44.0/64.8) and SAEs (PsA = 8.1/13.6; RA = 8.0/9.5) were higher with MR versus IR. AE RRs (RA) in the first 4 years after IR approval were 95.9 (IR; 49,439 PY) and 147.0 (MR; 2000 PY). Frequency of SAEs, AESIs, and fatal cases was mostly similar across formulations and indications. The most frequently-reported AE Preferred Terms (PsA/RA) included drug ineffective (20.0%/17.8%), pain (9.7%/10.6%), condition aggravated (9.9%/10.5%), headache (8.8%/7.9%) and, for PsA, off-label use (10.5%/3.4%). Conclusions: Tofacitinib PMS safety data from submitted AE reports were consistent between PsA and RA, and aligned with its known safety profile. Exposure data (lower MR versus IR; estimation from commercial sales data), reporting bias, reporter identity, and regional differences in formulation use limit interpretation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.
- Author
-
Cohen, Stanley, Curtis, Jeffrey R., DeMasi, Ryan, Chen, Yan, Fan, Haiyun, Soonasra, Arif, and Fleischmann, Roy
- Subjects
- *
RHEUMATOID arthritis treatment , *ADVERSE health care events , *JANUS kinases , *DRUG approval , *TUMORS - Abstract
Introduction: Post-marketing surveillance (PMS) is an integral part of monitoring adverse events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). An analysis of PMS reports was conducted to evaluate the safety of tofacitinib in a post-marketing setting.Methods: Worldwide tofacitinib PMS data received in the Pfizer safety database from November 6, 2012 (first marketing authorization of tofacitinib) to November 5, 2015 were analyzed. Serious AEs (SAEs) of interest were reviewed and reporting rates (RRs) were calculated by dividing the number of SAEs by the estimated 100 patient-years of exposure. Patient exposure was calculated based on estimated worldwide sales and an estimated daily regimen of tofacitinib 5 mg twice daily.Results: During the 3-year reporting period, worldwide post-marketing exposure to tofacitinib since approval was estimated to be 34,223 patient-years. In total, 9291 case reports (82.9% non-serious) were received and 25,417 AEs, 102 fatal cases, and 4352 SAEs were reported. The RRs (per 100 patient-years) for SAEs of interest by Medical Dictionary for Regulatory Activities System Organ Class were 2.57 for infections, 0.91 for gastrointestinal disorders, 0.60 for respiratory disorders, 0.45 for neoplasms, 0.43 for cardiac disorders, and 0.12 for hepatobiliary disorders.Conclusions: Although there are limitations to these data, no new safety risks were revealed in this real-world setting compared with the safety profile identified in the tofacitinib RA clinical development program. Any risks identified through the tofacitinib development program and PMS will continue to be monitored through pharmacovigilance surveillance.Funding: Pfizer Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis.
- Author
-
Conaghan, Philip G., Cohen, Stanley B., Berenbaum, Francis, Bodick, Neil, Lufkin, Joelle, and Johnson, James R.
- Subjects
- *
ANALGESICS , *CLINICAL trials , *CONFIDENCE intervals , *CONTROLLED release preparations , *DRUG delivery systems , *INTRA-articular injections , *KNEE diseases , *OSTEOARTHRITIS , *PAIN measurement , *TRIAMCINOLONE , *TREATMENT effectiveness , *TREATMENT duration , *KNEE pain , *THERAPEUTICS - Abstract
Objective: FX006 is a novel, microsphere‐based, extended‐release formulation of triamcinolone acetonide for intraarticular (IA) injection designed to maintain treatment concentration in the joint and provide prolonged analgesic benefits in patients with osteoarthritis (OA) of the knee. This study was undertaken to compare the analgesic benefits of 2 FX006 doses with saline placebo injection. Methods: In this phase IIb study, participants with knee OA (Kellgren/Lawrence grade 2–3) and average daily pain (ADP) intensity ≥5 to ≤9 (on a 0–10 Numerical Rating Scale) were randomized (1:1:1) to receive single IA injections of FX006 32 mg (n = 104) or 16 mg (n = 102) or saline placebo (n = 100). The primary end point was the least squares mean (LSM) change from baseline to week 12 in weekly mean ADP intensity scores for FX006 32 mg versus saline placebo. Results: The primary end point was not met (LSM change at week 12 −3.1 with FX006 32 mg versus −2.5 with saline placebo; LSM difference [95% confidence interval] −0.58 [−1.22, 0.07]) (
P = 0.08). However, improvements in ADP intensity were significantly greater with FX006 32 mg than saline placebo at weeks 1–11 and week 13. Improvements in ADP intensity were significantly greater with FX006 16 mg versus saline placebo at weeks 1–9. A dose‐response effect in duration of maximal analgesic effect was evident (13 weeks with 32 mg versus 9 weeks with 16 mg), with FX006 32 mg providing increased therapeutic benefit relative to FX006 16 mg. All treatments were well tolerated. Conclusion: Although the primary end point was not met, our findings indicate a prolonged reduction in symptoms with FX006 with an evident dose response and a safety profile similar to saline placebo. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.
- Author
-
Cohen, Stanley A., Aloi, Marina, Arumugam, Ramalingam, Baker, Robert, Bax, Kevin, Kierkuś, Jaroslaw, Koletzko, Sibylle, Lionetti, Paolo, Persson, Tore, Eklund, Stefan, and Kierkuś, Jaroslaw
- Subjects
- *
BUDESONIDE , *CROHN'S disease in children , *DISEASE remission - Abstract
Objective: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children.Methods: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6-17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9 mg or 6 mg once daily for 8 weeks; in the maintenance study, patients in remission received budesonide 6 mg once daily for 12 weeks. The primary objective was assessment of safety, including glucocorticosteroid-related side effects and serum cortisol levels. Efficacy was assessed using the Pediatric Crohn's Disease Activity Index (PCDAI), and health-related quality of life (HRQoL) using the IMPACT-III questionnaire.Results: In the induction study (n = 108), most adverse events were related to CD, commonly abdominal pain; possible glucocorticosteroid-related effects included acne and increased appetite but without significant weight gain. Subnormal morning cortisol levels were observed in 32 of 103 patients after 8 weeks. Budesonide reduced disease activity from baseline (mean ± standard deviation, 9.1 ± 8.5 vs. 19.1 ± 10.1, p < .001) with 58.1% of patients reaching remission (PCDAI <10); HRQoL improved (p < .001). In the maintenance study (n = 50), mean disease activity worsened (p = .047) with HRQoL unchanged (p = .33).Conclusions: Budesonide treatment was generally well tolerated, although the potential for adrenal suppression was noted. Budesonide was effective for induction of remission in children with mild-to-moderate CD but not for maintaining remission (ClinicalTrials.gov identifiers: NCT01444092, NCT01453946). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
18. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
- Author
-
Cohen, Stanley, Emery, Paul, Greenwald, Maria, Yin, Donghua, Becker, Jean‐Claude, Melia, Lisa Ann, Li, Ruifeng, Gumbiner, Barry, Thomas, Dolca, Spencer‐Green, George, and Meng, Xu
- Subjects
- *
RITUXIMAB , *BIOLOGICAL products , *RHEUMATOID arthritis treatment , *PHARMACODYNAMICS , *PHARMACOKINETICS , *CONFIDENCE intervals - Abstract
Aims Pharmacokinetic (PK) similarity was assessed among PF-05280586 (a proposed biosimilar) vs. rituximab sourced from the European Union (rituximab-EU) and the United States (rituximab-US). Pharmacodynamics (PD), overall safety and immunogenicity were also evaluated. Methods Patients with active rheumatoid arthritis on a background of methotrexate and inadequate response to one or more tumour necrosis factor antagonist therapies were randomized to intravenous PF-05280586, rituximab-EU or rituximab-US 1000 mg doses on study days 1 and 15. Results A total of 220 patients were randomized to receive study treatment as assigned. Of these, 198 met per-protocol population criteria for inclusion in the PK data analysis. PF-05280586, rituximab-EU and rituximab-US exhibited similar PK profiles following administration of assigned study drug on days 1 and 15. The 90% confidence intervals of test-to-reference ratios for Cmax, AUCT, AUC0-∞ and AUC2-week were within the bioequivalence margin of 80.00-125.00% for comparisons of PF-05280586 with rituximab-EU, PF-05280586 with rituximab-US, and rituximab-EU with rituximab-US. All treatments resulted in a rapid and profound reduction in CD19+ B cells and sustained profound B cell suppression up to week 25. The incidence of antidrug antibody (ADA) response ( n = 7, 10 and 9 for PF-05280586, rituximab-EU and rituximab-US, respectively), time to ADA emergence and ADA titres were similar across treatments. None of the ADA-positive samples was positive for neutralizing activity. No clinically meaningful differences in adverse events were identified. Conclusions The study demonstrated PK similarity among PF-05280586, rituximab-EU and rituximab-US. In addition, all treatments showed comparable CD19+ B cell depletion PD responses, as well as safety and immunogenicity profiles. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
19. Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate Combination.
- Author
-
Cohen, Stanley B., Haraoui, Boulos, Curtis, Jeffrey R., Smith, Timothy W., Woolcott, John, Gruben, David, and Murray, Christopher W.
- Published
- 2022
- Full Text
- View/download PDF
20. The use of a patency capsule in pediatric Crohn's disease: a prospective evaluation.
- Author
-
Cohen, Stanley, Gralnek, Ian, Ephrath, Hagit, Stallworth, Angela, Wakhisi, Tamara, Cohen, Stanley A, and Gralnek, Ian M
- Subjects
- *
CROHN'S disease in children , *CAPSULE endoscopy , *MEDICAL screening , *INFLAMMATORY bowel diseases , *SMALL intestine , *CROHN'S disease diagnosis , *PATIENTS , *ULCERATIVE colitis diagnosis , *CLINICAL trials , *COMPARATIVE studies , *ENDOSCOPES , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research - Abstract
Background: Capsule endoscopy (CE) retention remains a concern in patients with suspected or known Crohn's Disease (CD).Aim: The aim of this study was to evaluate the ability of a patency capsule (PC) to establish functional patency in pediatric patients with suspected or known, symptomatic IBD.Methods: A prospective, single center study evaluating the impact of CE on CD management used PC to qualify patients for CE. Patients excreting an intact PC, usually within 40 h of ingestion, were able to undergo standard video CE. Excretion time, structural integrity and patient safety were evaluated.Results: Eighteen patients (10-16 years of age; 9 male; 5 known CD, 3 indeterminate colitis, 1 ulcerative colitis, 9 suspected CD) ingested the PC. Fifteen patients excreted intact PC (mean 34.5 h), 12 patients within 40 h (range 9-60 h). Sixteen (89%) underwent subsequent CE successfully. CD was eventually diagnosed in all patients having PC transit ≥40 h, whereas CD was the diagnosis in 9/12 (75%) in those patients who passed the PC within 40 h. The mean time of passage for an intact PC was 34.7 h, the longest 60 h. There were no capsule retentions or adverse events.Conclusions: The PC appears to be a useful screening tool for functional patency of the small bowel in suspected or known pediatric CD. Delayed passage of an intact PC requires careful interpretation. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
21. Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
- Author
-
Cohen, Stanley, Radominski, Sebastião C., Gomez‐Reino, Juan J., Wang, Lisy, Krishnaswami, Sriram, Wood, Susan P., Soma, Koshika, Nduaka, Chudi I., Kwok, Kenneth, Valdez, Hernan, Benda, Birgitta, and Riese, Richard
- Subjects
- *
TUBERCULOSIS epidemiology , *CONFIDENCE intervals , *CAUSES of death , *ENZYME inhibitors , *HEPATITIS , *HERPES zoster , *INFECTION , *MORTALITY , *NEUTROPHILS , *OPPORTUNISTIC infections , *PHOSPHOTRANSFERASES , *RESEARCH funding , *RHEUMATOID arthritis , *SECONDARY analysis , *PROPORTIONAL hazards models , *LYMPHOCYTE count , *CHEMICAL inhibitors - Abstract
Objective To determine the rate of infection and all-cause mortality across tofacitinib phase II, phase III, and long-term extension (LTE) studies in patients with moderately to severely active rheumatoid arthritis (RA). Methods Pooled data from studies of tofacitinib in patients with RA were analyzed. In these studies, tofacitinib was administered as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. The cutoff date for inclusion of data was April 19, 2012. Results Across phase II, phase III, and LTE studies, 4,789 patients received tofacitinib (8,460 patient-years of exposure). The overall rate of serious infection was 3.09 events per 100 patient-years (95% confidence interval [95% CI] 2.73-3.49), and rates were stable over time. A Cox proportional hazards model showed that age, corticosteroid dose, diabetes, and tofacitinib dose were independently linked to the risk of serious infection. Lymphocyte counts of <0.5 × 103/mm3 were rare but were associated with an increased risk of treated and/or serious infection. Overall, all-cause mortality rates were 0.30 events per 100 patient-years (95% CI 0.20-0.44). Conclusion The overall risk of infection (including serious infection) and mortality rates in RA patients treated with tofacitinib appear to be similar to those observed in RA patients treated with biologic agents. The rates of serious infection were stable over time. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
22. JAK inhibitors and VTE risk: how concerned should we be?
- Author
-
Cohen, Stanley B.
- Subjects
- *
THROMBOEMBOLISM , *RHEUMATOID arthritis , *TEMPERING , *ENTHUSIASM - Abstract
Janus kinase (JAK) inhibitors have become standard treatment for patients with rheumatoid arthritis who do not respond well to other DMARDs. Concerns have been raised over an increased risk of venous thromboembolism with JAK inhibitors, tempering enthusiasm for their use in the clinic, but are these concerns justified? [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. The evolution of anatomic pathology.
- Author
-
Cohen, Stanley and Coffman, Frederick
- Subjects
- *
ANATOMY , *PATHOLOGY , *TISSUES , *CELLS , *RADIOLOGY , *DIAGNOSTIC imaging - Abstract
Science advances both by conceptual leaps and by improved observational and analytic tools. Mechanism and function in biological systems can best be understood in the context of the complex microenvironments in which they occur, and for this purpose morphologic analysis can be critical. Technological advances in cell and tissue imaging are currently finding application in a wide variety of basic, translational, and clinical biomedical studies. 'Biophotonics in Pathology' was designed as a multi-authored work to describe the various kinds of imaging strategies that have been developed as computational power keeps increasing. Some of these overlap with radiologic techniques and others do not. The field is continuously evolving, and in this commentary I will touch on additional techniques for morphology-based interrogation of cells and tissues that have recently been described. However, it is important to note that though we are expanding our armamentarium as pathologists, our radiological colleagues have been doing this for many years. Clearly, they have embraced new imaging techniques to a greater extent than have pathologists. This commentary discusses some of the factors responsible for this, and suggests that pathology and radiology are converging towards a more holistic approach to diagnostic imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. DNA cloning: A personal view after 40 years.
- Author
-
Cohen, Stanley N.
- Subjects
- *
MOLECULAR cloning , *PLASMIDS , *DNA , *GENETIC recombination , *MOBILE genetic elements , *GENETIC engineering - Abstract
In November 1973, my colleagues A. C. Y. Chang, H. W. Boyer, Ft. B. Helling, and I reported in PNAS that individual genes can be cloned and isolated by enzymatically cleaving DIMA molecules into fragments, linking the fragments to an autonomously replicating plasmid, and introducing the resulting recombinant DNA molecules into bacteria. A few months later, Chang and I reported that genes from unrelated bacterial species can be combined and propagated using the same approach and that interspecies recombinant DNA molecules can produce a biologically functional protein in a foreign host. Soon afterward, Boyer's laboratory and mine published our collaborative discovery that even genes from animal cells can be cloned in bacteria. These three PNAS papers quickly led to the use of DNA cloning methods in multiple areas of the biological and chemical sciences. They also resulted in a highly public controversy about the potential hazards of laboratory manipulation of genetic material, a decision by Stanford University and the University of California to seek patents on the technology that Boyer and I had invented, and the application of DNA cloning methods for commercial purposes. In the 40 years that have passed since publication of our findings, use of DNA cloning has produced insights about the workings of genes and cells in health and disease and has altered the nature of the biotechnology and biopharmaceutical industries. Here, I provide a personal perspective of the events that led to, and followed, our report of DNA cloning. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Impedance measurements in the biomedical sciences.
- Author
-
Coffman, Frederick D. and Cohen, Stanley
- Subjects
- *
MEDICAL sciences , *ELECTRICAL impedance tomography , *DISEASE progression , *METABOLISM , *CYTOLOGICAL research , *ORGANISMS - Abstract
Biological organisms and their component organs, tissues and cells have unique electrical impedance properties. Impedance properties often change with changes in structure, composition, and metabolism, and can be indicative of the onset and progression of disease states. Over the past 100 years, instruments and analytical methods have been developed to measure the impedance properties of biological specimens and to utilize these measurements in both clinical and basic science settings. This chapter will review the applications of impedance measurements in the biomedical sciences, from whole body analysis to impedance measurements of single cells and cell monolayers, and how cellular impedance measuring instruments can now be used in high throughput screening applications. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
26. A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone.
- Author
-
Kremer, Joel M., Cohen, Stanley, Wilkinson, Bethanie E., Connell, Carol A., French, Jonathan L., Gomez-Reino, Juan, Gruben, David, Kanik, Keith S., Krishnaswami, Sriram, Pascual-Ramos, Virginia, Wallenstein, Gene, and Zwillich, Samuel H.
- Abstract
Objective. To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy. Methods. In this 24‐week, double‐blind, phase IIb study, patients with active RA (n = 507) were randomized to receive placebo or tofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily). All patients continued to receive a stable dosage of MTX. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Results. At week 12, ACR20 response rates for patients receiving all tofacitinib dosages ≥3 mg twice daily (52.9% for 3 mg twice daily, 50.7% for 5 mg twice daily, 58.1% for 10 mg twice daily, 56.0% for 15 mg twice daily, and 53.8% for 20 mg/day) were significantly (P ≤ 0.05) greater than those for placebo (33.3%). Improvements were sustained at week 24 for the ACR20, ACR50, and ACR70 responses, scores for the Health Assessment Questionnaire disability index, the 3‐variable Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP), and a 3‐variable DAS28‐CRP of <2.6. The most common treatment‐emergent adverse events occurring in >10% of patients in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 patients (4.1%) experienced serious adverse events. Sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decreases in neutrophil and hemoglobin levels were observed. Conclusion. In patients with active RA in whom the response to MTX has been inadequate, the addition of tofacitinib at a dosage ≥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
27. Small Bowel Capsule Endoscopy Impacts Diagnosis and Management of Pediatric Inflammatory Bowel Disease: A Prospective Study.
- Author
-
Gralnek, Ian, Cohen, Stanley, Ephrath, Hagit, Napier, Angela, Gobin, Tamara, Sherrod, Olga, and Lewis, Jeffrey
- Subjects
- *
INFLAMMATORY bowel diseases , *CAPSULE endoscopy , *CROHN'S disease , *ULCERATIVE colitis , *QUESTIONNAIRES , *LONGITUDINAL method , *COHORT analysis , *DECISION making - Abstract
Purpose: Accurately classifying inflammatory bowel disease (IBD) type in pediatric patients may impact medical decision-making, direct therapy, and improve outcomes. Methods: This was a prospective cohort study evaluating classification of IBD and patient management with use of capsule endoscopy in pediatric patients with suspected or known IBD. Treating physicians completed a questionnaire before and after capsule endoscopy (CE) assessing clinical suspicion of Crohn's disease (CD) diagnosis, patient management decisions, and perceived impact of CE findings. Results: Eighteen subjects [11F/7M, mean age 13.8 (±2.5) years], 4 previously diagnosed with CD, 4 with ulcerative or indeterminate colitis (UC/IC), and 10 'suspected' to have IBD were included. Following CE, 2 of 4 (50%) UC/IC patients were reclassified as having small bowel CD. In the 4 subjects with known CD, 2 (50%) had CE evidence of more proximal small bowel mucosal disease than previously recognized. In the 10 subjects with 'suspected' IBD, 8 (80%) had SB ulcerations leading to a definitive diagnosis of CD. Treating physicians reported CE helped diagnosing CD in 15 of 18 (83.3%) subjects and impacted medical decision-making in 13 of 18 (72.2%), leading to a change in medical management in 14 of 18 (77.8%). Conclusions: In 'suspected' pediatric IBD, CE often leads to a definitive diagnosis of CD. CE can lead to reclassification of IBD from UC/IC to CD and previously diagnosed CD patients may have a more significant burden of small bowel disease. These data may help integrate CE in evaluating IBD patients, lead to more targeted medical management changes and improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. Prevention of Hepatitis B Recurrence in Liver Transplant Patients Using Oral Antiviral Therapy without Long-Term Hepatitis B Immunoglobulin.
- Author
-
Ahn, Joseph and Cohen, Stanley Martin
- Published
- 2011
- Full Text
- View/download PDF
29. Prevention of Hepatitis B Recurrence in Liver Transplant Patients Using Oral Antiviral Therapy without Long-Term Hepatitis B Immunoglobulin.
- Author
-
Ahn, Joseph and Cohen, Stanley Martin
- Subjects
- *
HEPATITIS B prevention , *DISEASE relapse , *ACADEMIC medical centers , *ANTIVIRAL agents , *CHI-squared test , *IMMUNOGLOBULINS , *LIVER transplantation , *ORAL drug administration , *HEALTH outcome assessment , *STATISTICS , *DATA analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics ,DISEASE relapse prevention - Abstract
Background: Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. Objectives: This larger study evaluates the use of NAT with short term (< 6 mo) or no HBIG for prevention of post-LT HBV recurrence. Patients and Methods: All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival. Results: 28 study patients were identified. Of these 28 patients, 4 (14%) received no HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and outpatient HBIG. 16 of the 28 patients (57%) received combination NAT and 12 patients (43%) received single NAT. At a median time of 15.5 months (range 9-24 months) post- LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance. Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
30. A Pilot Study of Rituximab in Immune-Mediated Inner Ear Disease.
- Author
-
Cohen, Stanley, Roland, Peter, Shoup, Angela, Lowenstein, Mitchell, Silverstein, Herbert, Kavanaugh, Arthur, and Harris, Jeffrey
- Subjects
- *
INNER ear diseases , *HEARING disorders , *ADRENOCORTICAL hormones , *HORMONE therapy , *IMMUNOGLOBULINS , *PROTEINS , *RITUXIMAB , *PHARMACODYNAMICS - Abstract
Immune-mediated inner ear disease (IMED) is a cause of rapidly progressive auditory dysfunction. Patients are often responsive to high-dose corticosteroids and the disease is believed to be mediated by an antibody to inner ear proteins. To date, no therapies have proven effective as corticosteroid-sparing agents. Rituximab is a monoclonal antibody that depletes B cells, resulting in a reduction in autoantibody production. For that reason, rituximab was evaluated in a small pilot study in patients with IMED to see if there was a signal suggesting benefit. In all, 5/7 patients met the primary endpoint of an improvement in pure tone average (500-3000 Hz) by 10 dB in at least one ear, or an improvement in word identification score by at least 12% at 24 weeks, both relative to screening precorticosteroid values after 1 course of treatment. No significant adverse events were reported. The results of this study suggest further evaluation of rituximab as a treatment for IMED is indicated. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
31. Ideology? What ideology?
- Author
-
Cohen, Stanley
- Subjects
- *
GOVERNMENT policy - Abstract
The author focuses on the exercise of theory construction in the books "Punishing the Poor" and "Prisons and Poverty" both by Loic Wacquant. He discusses the attempt of the author to warn European governments on the negative effects of U.S. policies. He explains the link of power to knowledge in the implementation of changes that exemplifies internal insecurity. He emphasizes the practice of think-tanks to circulate information on knowledge.
- Published
- 2010
- Full Text
- View/download PDF
32. A pilot study of rituximab in immune-mediated inner ear disease.
- Author
-
Cohen, Stanley, Roland, Peter, Shoup, Angela, Lowenstein, Mitchell, Silverstein, Herbert, Kavanaugh, Arthur, and Harris, Jeffrey
- Published
- 2010
33. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
- Author
-
Cohen, Stanley, Zwillich, Samuel H., Chow, Vincent, LaBadie, Robert R., and Wilkinson, Bethanie
- Subjects
- *
METHOTREXATE , *RHEUMATOID arthritis , *PHARMACOKINETICS , *THERAPEUTICS , *DRUG side effects - Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • CP-690,550 is a novel JAK inhibitor in development as a therapy for rheumatoid arthritis. • Methotrexate is the cornerstone of combination treatment for rheumatoid arthritis. • The safety and tolerability of co-administration of CP-690,550 with methotrexate have not been addressed to date. WHAT THIS STUDY ADDS • This study in patients with rheumatoid arthritis shows that there are no clinically relevant effects on the pharmacokinetics of either drug following short-term co-administration. • Co-administration of CP-690,550 and methotrexate was safe and well tolerated. AIMS To investigate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550, a novel Janus kinase (JAK) inhibitor in development as a therapy for rheumatoid arthritis (RA), to determine the effects of multiple doses of CP-690,550 on the PK of MTX, and to evaluate the short-term safety and tolerability of co-administration of CP-690,550 and MTX. METHODS This was a fixed-dose drug–drug interaction study. Twelve patients diagnosed with RA for at least 6 months were enrolled in a Phase I, open-label study of the PK of multiple doses of CP-690,550 (30 mg b.i.d.) and single doses of MTX (15–25 mg per week). RESULTS All patients completed the study and were evaluated for PK and safety. CP-690,550 exposure was not affected by co-administration with MTX; AUC12 ratio (CP-690,550 + MTX/CP-690,550) was 103.06% [90% confidence interval (CI) 99.00, 107.29]. MTX exposure decreased by 10%; AUC12 ratio (CP-690,550 + MTX/MTX) was 89.53% (90% CI 77.38, 103.57), which was not considered clinically significant. Co-administration of CP-690,550 and MTX was safe and well tolerated. There were no serious adverse events or withdrawals from the study and there was no trend in the incidence or severity of adverse events across treatments. CONCLUSIONS Co-administration of CP-690,550 and MTX was safe and well tolerated. There was no clinically significant effect on the PK profile of either drug. Therefore, dose adjustments should not be required when co-administering CP-690,550 and MTX. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
34. Use of Antithrombotic Agents Among U.S. Stroke Survivors, 2000–2006
- Author
-
Cheng, Eric M., Cohen, Stanley N., Lee, Martin L., Vassar, Stefanie D., and Chen, Alex Y.
- Subjects
- *
ANTICOAGULANTS , *CEREBROVASCULAR disease prevention , *ASPIRIN , *PLATELET aggregation inhibitors , *OUTPATIENT medical care , *MULTIVARIATE analysis - Abstract
Background: Secondary stroke prevention guidelines recommend antithrombotic agents such as over-the-counter aspirin, prescription antiplatelet agents, or anticoagulant agents. Purpose: The study was designed to measure whether use of outpatient antithrombotic agents is increasing among stroke survivors. Methods: The sample consisted of 4168 people who self-reported cerebrovascular disease and who participated in the Medical Expenditure Panel Survey, an annual representative sample of the U.S., during the years 2000–2006. Use of antithrombotic agents was calculated from face-to-face interviews about the use of aspirin and from pharmacies about the use of prescription medications. Cochran–Armitage tests were used to detect temporal trends and multivariate models to identify predictors of use of antithrombotic agents. Results: Pooling results across the 7 years, it was found that 57% were taking aspirin, 66% were using any antiplatelet agent, and 75% were using any antithrombotic agent. After excluding people who said aspirin was unsafe, 81% were using any antithrombotic agent. During the study period, use of prescription antiplatelet agents increased (p<0.001) but there was no temporal change in use of antithrombotic agents overall. In multivariate models, being aged >65 years, male gender, non-Hispanic ethnicity, having a usual source of care, and poor or fair health status were associated with use of an antithrombotic agent (p<0.05). Conclusions: Although a high percentage of stroke survivors appear to use an antithrombotic agent, further research should investigate whether and how to improve care among the remaining 20% of stroke survivors, particularly among younger, female, and Hispanic patients. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
35. Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.
- Author
-
Burmester, Gerd R., Coates, Laura C., Cohen, Stanley B., Tanaka, Yoshiya, Vranic, Ivana, Nagy, Edward, Lazariciu, Irina, Chen, All-shine, Kwok, Kenneth, Fallon, Lara, and Kinch, Cassandra
- Subjects
- *
RHEUMATOID arthritis , *PSORIATIC arthritis - Abstract
The original article titled "Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis" has issued a correction notice. The correction pertains to Table 5 of the article, which contained incorrect values for serious adverse events (SAEs) within the rheumatoid arthritis (RA) section for different patient subgroups. The correct values for the age ≥ 65 years, female sex, and male sex patient subgroups are 21.27%, 16.50%, and 19.06%, respectively. The corrected table is provided in the correction notice. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
36. Evaluation of the Efficacy and Safety of Pamapimod, a p38 MAP Kinase Inhibitor, in a Double-Blind, Methotrexate-Controlled Study of Patients With Active Rheumatoid Arthritis.
- Author
-
Cohen, Stanley B., Tien-Tsai Cheng, Chindalore, Vishala, Damjanov, Nemanja, Burgos-Vargas, Ruben, DeLora, Patricia, Zimany, Kathleen, Travers, Helen, and Caulfield, John P.
- Subjects
- *
DRUG efficacy , *RHEUMATOID arthritis , *METHOTREXATE , *IMMUNOLOGY , *ELECTROCARDIOGRAPHY , *THERAPEUTICS - Abstract
The article discusses the study which ais to determine the efficacy and safety of pamapimod as monotherapy with methotrexate treatment in patients with active rheumatoid arthritis (RA). The study applied safety monitoring including laboratory testing, immunology assessments, administration of electrocardiograms and assessment of vital signs. Thus, the study found that pamapimed was not as effective as methotrexate in the treatment of active RA.
- Published
- 2009
- Full Text
- View/download PDF
37. Origins of Growth Factors: NGF and EGF.
- Author
-
Cohen, Stanley
- Subjects
- *
GROWTH factors , *EPIDERMAL growth factor , *NERVE growth factor , *SCIENTIFIC experimentation , *FIBROBLASTS - Abstract
The article presents the origin of growth factors such as nerve growth factor (NGF) and epidermal growth factor (EGF). The author explains that the original neuroembryological experiments started in the laboratories of Drs. Viktor Hamburger and Rita Levi-Montalcini. Then, the author got involved in the experiment and decided to examine some of the metabolic effects of EGF on epidermal cultures. Pedro Cuatrecasas discovered that EGF can stimulate the growth of human fibroblasts when cultured.
- Published
- 2008
- Full Text
- View/download PDF
38. Denosumab Treatment Effects on Structural Damage, Bone Mineral Density, and Bone Turnover in Rheumatoid Arthritis.
- Author
-
Cohen, Stanley B., Dore, Robin K., Lane, Nancy E., Ory, Peter A., Peterfy, Charles G., Sharp, John T., Van der Heijde, Désirée, Zhou, Lifen, Tsuji, Wayne, and Newmark, Richard
- Subjects
- *
RHEUMATOID arthritis , *MONOCLONAL antibodies , *METHOTREXATE , *BIOMARKERS , *BONE injuries - Abstract
The article details a study which evaluated the effects of denosumab on structural damage in patients diagnosed with rheumatoid arthritis (RA) receiving methotrexate treatment. The study found that denosumab caused sustained suppression of markers of bone turnover. It concluded that the addition of twice-yearly injections of denosumab to ongoing methotrexate treatment inhibited structural damage in RA patients.
- Published
- 2008
- Full Text
- View/download PDF
39. Spirituality and Cognition: Does Spirituality Influence What We Attend to and Remember?
- Author
-
Verno, Karri, Cohen, Stanley, and Patrick, Julie
- Subjects
- *
MENTAL discipline , *THOUGHT & thinking , *SPIRITUALITY , *SPIRITUAL direction , *POSITIVISM , *NEGATIVISM , *INDIVIDUALISM , *PERSONALITY development , *PERSONALITY assessment - Abstract
This study investigated how spirituality as a positive life theme might be related to one’s unique style of cognitive processing. Study participants included 80 individuals; 40 older adults and 40 younger adults. Word recall and recognition tasks assessed memory for positive, negative, neutral, and religious words. Results indicated that spirituality does not appear to be related to cognitive bias, but that words with either positive, negative, neutral, or religious connotations are recalled and recognized at different rates. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
40. Psychology as a Profession: An Effective Career Exploration and Orientation Course for Undergraduate Psychology Majors.
- Author
-
Macera, Michelle Heffner and Cohen, Stanley H.
- Subjects
- *
VOCATIONAL guidance , *PSYCHOLOGY education , *CAREER development , *COUNSELING in higher education , *GRADUATE education , *PSYCHOLOGY , *EDUCATIONAL counseling , *HIGHER education , *STUDENTS - Abstract
The authors describe an undergraduate psychology course that covers academic advising and career planning. Lectures included choosing a major, job opportunities with a bachelor's degree, applying to graduate school, and guest lectures from professionals in psychology-related careers. Students completed a plan of study, a résumé, and a career exploration paper. Students evaluated the course and assignments as being moderately high in value and recommended that the course continue to be required for psychology majors. Nearly all students (93%) either changed their career plans or felt more confident about their plans after taking the course. Recommendations for implementing a similar course are provided. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
41. The liver transplant recipient: What you need to know for long-term care.
- Author
-
Levitsky, Josh and Cohen, Stanley Martin
- Subjects
- *
LIVER transplantation , *SURGICAL complications , *COMPLICATIONS from organ transplantation , *DRUG interactions , *GRAFT rejection , *BILIARY tract , *THROMBOSIS , *VIRUSES , *HERPES simplex , *TRANSPLANTATION immunology - Abstract
The article discusses the orthotopic liver transplantation (OLT) and its complications. OLT is the replacement of a whole diseased liver with a healthy donor liver. In less than a year, complications may be already experienced such as acute graft rejection, vascular thrombosis, biliary leak or stricture, and infection. According to the author, a broad range of infections may develop, including cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zooster virus, and tuberculosis. Tables are presented showing common complications, immunosuppresive medications, and interactions after liver transplantation.
- Published
- 2006
42. Preventing recurrent ischemic stroke: A 3-step plan.
- Author
-
Cohen, Stanley N.
- Subjects
- *
CEREBROVASCULAR disease patients , *BLOOD circulation disorders , *ANTIHYPERTENSIVE agents , *BLOOD pressure , *ARTERIAL stenosis , *MEDICAL care - Abstract
The article presents information on a 3 step plan to prevent the reoccurrence of ischemic stroke. To prevent recurrent stroke, address the patient's risk factors, clear stenosis, and thin the blood Once a stroke patient has stabilized, if there is no contraindication, one should consider starting an antihypertensive agent regardless of the baseline blood pressure. For symptomatic patients with high grade carotid stenosis (70% to 99%), one should plan a course of medical management plus carotid endarterectomy (CEA). With moderate carotid stenosis (50% to 69%), CEA offers only moderate stroke risk reduction or patients with atherosclerotic ischemic infarction, 3 steps are needed to achieve the goal of preventing recurrent stroke address risk factors, clear blocked arteries, and thin the blood. INSET: The risks and costs of stroke.
- Published
- 2005
43. Evaluating Student Use of Web-Based Course Material.
- Author
-
Heffner, Michelle and Cohen, Stanley H.
- Subjects
- *
ONLINE education , *COMPUTER software , *TEACHING aids , *COMPUTER assisted instruction , *INTERNET in education - Abstract
Course management software and on-line course material are becoming more available. As a result, many instructors have developed WebCT course Web sites to deliver on-line course material that supplements lecture topics. The present study examined associations between student characteristics, course performance, and access of Web-CT course material. We tracked and coded patterns of Web usage by 154 students in a Psychology as a Profession course. Frequency of student access to Web-based material correlated positively with grades on course assignments. Females accessed the home page more often than males. Self-reports from students evaluated the course Website as highly valuable. These results suggest important advantages in supplementing lecture courses with on-line material. [ABSTRACT FROM AUTHOR]
- Published
- 2005
44. Smurf2 up-regulation activates telomere dependent senescence.
- Author
-
Hong Zhang and Cohen, Stanley N.
- Subjects
- *
TELOMERES , *AGING , *SOMATIC cells , *LIGASES , *PROTEINS - Abstract
Progressive telomere shortening activates replicative senescence, which prevents somatic cells from being propagated indefinitely in culture. The limitation of proliferative capacity imposed by replicative senescence is thought to contribute to both organismal aging and the prevention of tumor development. Here we report that up-regulation of Smurf2, an E3 ubiquitin ligase previously implicated in TGF-β signaling, is a specific consequence of telomere attrition in human fibroblasts and that such up-regulation is sufficient to produce the senescence phenotype. Adventitious production of the Smurf2 protein in early passage fibroblasts at the same physiological level observed during telomere-mediated senescence resulted in proliferative arrest in a viable state, morphological and biochemical alterations characteristic of senescence, acquisition of senescence-specific alterations in gene expression, and reversal of cellular immortalization by telomerase. We show that the senescence-inducing actions of Smurf2 occur in the absence of detectable DNA damage or stress response, that Smurf2's effects require a novel function distinct from its E3 activity, that Smurf2 recruits the Rb and p53 pathways for senescence induction, and that while p21 is elevated by Smurf2, Smurf2-mediated senescence is independent of p21. Smurf2 is the first gene found to be both up-regulated by telomere attrition and sufficient to induce senescence. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
45. Fairness: How to Achieve It and How to Optimize in a Fair-Division Procedure.
- Author
-
Jones, Michael A. and Cohen, Stanley F.
- Subjects
- *
MATHEMATICS , *CONFLICT management , *FAIRNESS , *MATHEMATICAL optimization , *MATHEMATICAL analysis - Abstract
Describes the application of mathematics to dispute resolution. Explanation on the basic properties of fair divisions; Illustration of how such properties are mathematically met; Introduction of the adjusted-winner procedure of dividing disputed goods.
- Published
- 2004
46. Comments on Simon Cottee's 'Folk devils and moral panics: 'Left idealism' reconsidered', in Theoretical Criminology 6(4).
- Author
-
Cohen, Stanley and Young, Jock
- Subjects
- *
RADICALISM , *IDEALISM , *SOCIAL constructionism , *CRIMINOLOGY , *POLITICAL science , *PHILOSOPHY - Abstract
Comments on the article "Folk devils and moral panics: "Left idealism" reconsidered', in Theoretical Criminology," by Simon Cottee. Critique of the idea of Left Idealism or of the separate ideas subsumed under this label; Allusions to contemporary versions of social constructionism.
- Published
- 2004
- Full Text
- View/download PDF
47. A Streptomyces coelicolor functional orthologue of Escherichia coli RNase E shows shuffling of catalytic and PNPase-binding domains.
- Author
-
Lee, Kangseok and Cohen, Stanley N.
- Subjects
- *
RIBONUCLEASES , *STREPTOMYCES coelicolor , *PHOSPHORYLASES - Abstract
Summary: Previous work has detected an RNase E-like endoribonucleolytic activity in cell extracts obtained from Streptomyces. Here, we identify a Streptomyces coelicolor gene, rns, encoding a 140 kDa protein (RNase ES) that shows endoribonucleolytic cleavage specificity characteristic of RNase E, confers viability on and allows propagation of Escherichia coli cells lacking RNase E and accomplishes RNase E-like regulation of plasmid copy number in E. coli. However, notwithstanding its complementation of rne-deleted E. coli, RNase ES did not accurately process 9S rRNA from E. coli. Additionally, whereas RNase E is normally required for E. coli survival, rns is not an essential gene in S. coelicolor. Deletion analysis mapped the catalytic domain of RNase ES near its centre and showed that regions located near the RNase ES termini interact with an S. coelicolor homologue of polynucleotide phosphorylase (PNPase) – a major component of E. coli RNase E-based degradosomes. The interacting arginine- and proline-rich segments resemble the C-terminally located degradosome scaffold region of E. coli RNase E. Our results indicate that RNase ES is a structurally shuffled RNase E homologue showing evolutionary conservation of functional RNase E-like enzymatic activity, and suggest the existence of degradosome-like complexes in Gram-positive bacteria.. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
48. Recruitment of terminal protein to the ends of Streptomyces linear plasmids and chromosomes by a novel telomere-binding protein essential for linear DNA replication.
- Author
-
Kai Bao and Cohen, Stanley N.
- Subjects
- *
DNA-binding proteins , *DNA replication , *STREPTOMYCES , *STREPTOMYCETACEAE , *GENES , *POLYMERASE chain reaction , *MOLECULAR genetics - Abstract
Deals with a study which examined the role of an 80-kD DNA-binding protein in the bidirectional replication of Streptomyces linear plasmids and chromosomes. DNA-binding properties of the Tap and Tpg proteins; Significance of Tap in the propagation of Streptomyces chromosomes and plasmids in linear form; Details on reverse transcriptase polymerase chain reaction experiments.
- Published
- 2003
- Full Text
- View/download PDF
49. Survival mechanisms for Streptomyces linear replicons after telomere damage.
- Author
-
Qin, Zhongjun and Cohen, Stanley N.
- Subjects
- *
STREPTOMYCES , *DNA , *BACTERIAL genetics - Abstract
Summary The ability of linear replicons to propagate their DNA after telomere damage is essential for perpetuation of the genetic information they carry. We introduced deletions at specific locations within telomeres of streptomycete linear plasmids and investigated mechanisms that enable survival. Here, we report that rescue of such plasmids in Streptomyces lividans occurs by three distinct types of events: (i) repair of the damaged telomere by homologous recombination; (ii) circularization of the plasmid by non-homologous end-to-end joining; and (iii) formation of long palindromic linear plasmids that duplicate the intact telomere by a non-recombinational process. The relative frequency of use of these survival mechanisms depended on the location and length of the telomeric DNA deletion. Repair by intermolecular recombination between the telomeres of chromosomes and plasmids, deletion of additional DNA during plasmid circularization, and insertion of chromosomal DNA fragments into plasmids during end-to-end joining were observed. Our results show that damage to telomeres of Streptomyces linear replicons can promote major structural transformations in these replicons as well as genetic exchange between chromosomes and extrachromosomal DNA. Our findings also suggest that spontaneous circularization of linear Streptomyces chromosomes may be a biological response to instances of telomere damage that cannot be repaired by homologous recombination. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
50. Mutational Analysis of the tra Locus of the Broad-Host-Range Streptomyces Plasmid pIJ101.
- Author
-
Pettis, Gregg S. and Cohen, Stanley N.
- Subjects
- *
STREPTOMYCES , *PLASMIDS , *MICROBIAL mutation , *BACTERIAL transformation - Abstract
Analyzes the mutation of the tra Locus of Streptomyces lividans plasmid pIJ101. Effects of the insertions in a 200-amino-acid region of the Tra protein on the plasmid and chromosomal transfer; Reduction in the Cma after insertions near the N terminus of Tra; Involvement of Cma in Tra functions needed for plasmid DNA transfer.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.